Neoadjuvant Treatment of Breast Cancer
Neoadjuvant Treatment of Breast Cancer - a Prospective Observational Study, PANnon ONCology (PANONC) Group Non-commercial Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: gabor Rubovszky
- Phone Number: 3442 +3612248600
- Email: garub@oncol.hu
Study Contact Backup
- Name: Balazs Madaras
- Phone Number: +3612248600
- Email: madarasb@oncol.hu
Study Locations
-
-
-
Budapest, Hungary, 1122
- National Institute of Oncolgy
-
Contact:
- Gabor Rubovszky, Ph D
- Phone Number: 3442 +3612248600
- Email: garub@oncol.hu
-
Contact:
- Balazs Madaras
- Phone Number: +3612248600
- Email: madarasb@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant over 18 years of age .
- Histologically confirmed (core biopsy) invasive breast tumor.
Tumor extent for the indication:
- regression must be achieved for radical surgical removal or
- regression is required for breast-conserving surgery or
- if hormone receptor (HR)-positive and Her2-: stage IIB (cT2N1 or cT3NO) - IIIC,
- if HR-negative: stage IIA (cT2N0 or cT0-1N1) - IIIC Note: In the case of a locally advanced, irresectable case, if the possibility of radical surgery later is a realistic goal, the participant may be included in the study.
- Appropriate general condition: ECOG 0-1
Proper organ function
- Neutrophil count ≥ 1.5 G / l, platelet count ≥ 100 G / l, hemoglobin ≥ 10 g / dl
- Alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is less than 1.5 times the upper limit of the normal range
- bilirubin less than 1.5 times the upper limit of the normal range (except Gilbert's disease, where less than 3 times)
- creatinine less than 1.5 times the upper limit of the normal range or estimated glomerular filtration rate (eGFR) higher than 60 ml / min
Exclusion Criteria:
- Proven or suspected distant metastasis.
- No staging studies have been performed: at least chest x-ray, abdominal ultrasound. It is preferred to perform CT from the chest, abdomen, pelvic regions and bone isotope, or PET / CT if possible in case of lymph node involvement.
- Known significant heart disease: major arrhythmia or significant conduction defect (grade 2 or more), infarction or unstable angina within 6 months, cardiac collapse without appropriate therapy, long QT syndrome, heart failure (≥New York Heart Association/NYHA II)
- Other severe acute or chronic conditions (organic or psychiatric illness, laboratory abnormality) that, in the opinion of the treating physician, result in an unacceptable increase in the risk of chemotherapy and are contraindicated in routine clinical practice.
- Pregnancy or if the participant does not agree to use an appropriate non-hormonal method of contraception.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
LuminalA
|
endocrine therapy
endocrine therapy
endocrine therapy
Other Names:
|
|
LuminalB (Her2 negative)
|
chemotherapy
endocrine therapy
endocrine therapy
endocrine therapy
Other Names:
chemotherapy
chemotherapy
chemotherapy
biological treatment
|
|
Her2 positive
|
chemotherapy
endocrine therapy
endocrine therapy
endocrine therapy
Other Names:
chemotherapy
chemotherapy
chemotherapy
biological treatment
biological treatment
|
|
Triple-negative breast cancer
|
chemotherapy
chemotherapy
chemotherapy
chemotherapy
chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pathological complete remission rate
Time Frame: 3 year, maximum
|
no invasive tumor in breast and axilla
|
3 year, maximum
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
invasive disease-free survival
Time Frame: 10 years
|
from the beginning of neoadjuvant therapy to the first appearance of invasive tumor or death
|
10 years
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Time Frame: 4 years
|
Global health status, functional and symptom scales survey using the EORTC QLQ-C30 questionnaire before cycle 1, before cycle 4, after the last neoadjuvant chemotherapy, and before surgery, 1 year after chemotherapy
|
4 years
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ BR45)
Time Frame: 4 years
|
Breast cancer-specific functional scales and symptom scales survey using the EORTC QLQ BR45 questionnaire before cycle 1, before cycle 4, after the last neoadjuvant chemotherapy, and before surgery, 1 year after chemotherapy
|
4 years
|
|
evaluation of side effects
Time Frame: 10 years
|
to collect information all potential complaints and adverse event during and after treatment
|
10 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
dose density assessment
Time Frame: 3 year, maximum
|
actual dose / planned dose
|
3 year, maximum
|
|
investigate the potential prognostic effect of neutrophil/lymphocyte ratio
Time Frame: 10 years
|
study of the role of neutrophil/lymphocyte ratio (NLR) at baseline, before the 3. cycle, and before surgery.
NLR is measured from the qualitative blood count as the absolute neutrophil count divided by the absolute lymphocyte count
|
10 years
|
|
investigate the potential prognostic effect of monocyte/lymphocyte ratio
Time Frame: 10 years
|
monocyte/lymphocyte ratio (MLR) at baseline, before the 3. cycle, and before surgery.
MLR is measured from the qualitative blood count as the absolute monocyte count divided by the absolute lymphocyte count
|
10 years
|
|
investigate potential prognostic factors, CRP
Time Frame: 10 years
|
C-reactive protein serum level befor start of chemotherapy
|
10 years
|
|
investigate potential prognostic factors
Time Frame: 10 years
|
circulating free-DNA at baseline, before 3. cycle, before surgery
|
10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gabor Rubovszky, NIO Hungary
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Bone Density Conservation Agents
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Docetaxel
- Cyclophosphamide
- Trastuzumab
- Capecitabine
- Epirubicin
- Letrozole
- Goserelin
- Tamoxifen
- Pertuzumab
Other Study ID Numbers
Other Study ID Numbers
- PANONC-1 Version: 1.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.